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ABSTRACT 
Objective: To evaluate the drug utilization of Angiotensin Receptor Blocker (ARB) along with their ADRs in a tertiary care hospital. And to monitor, 
report of adverse drug reaction and drug interactions, if any. 
Methods: The patients who meet the inclusion and exclusion criteria were enrolled into the study. The pertinent data such as demographic details, 
drug name, dose, frequency, and laboratory data were gathered from medical records of the patient and results were analyzed.  
Results: Total of 100 patients were included in this study, the maximum utilization of antihypertensive drug (ARB) was telmisartan (90%) and 
widely use of ARBs in the age group of 41-50 y. Total 32 ADRs were observed and most probable ADRs included headache (42.8%), Nausea 
(14.28%) and dizziness (12.5%). 
Conclusion: Telmisartan was the most prescribed and utilized drug than the other drugs of ARBs. Maximum ADRs were noted in females, the most 
frequent ADRs headache, nausea and dizziness were reported. The majority of reactions were probable on causality assessment done by WHO-UMC 
and Naranjo’s scale having mild severity. So it can be concluded that considering risk factors, prevention and management of ADRs can drastically 
improve the therapeutic outcomes of the patients.  
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INTRODUCTION 
Hypertension or elevated blood pressure (BP) is a most common 
problem felt by human in their daily life, mainly early adulthood and 
old age. It is not a disease in itself, but it is a serious medical 
condition that is significantly alarming signal for the heart and blood 
vessels related mortality and morbidity [1]. During 2010, Patients of 
Hypertension were estimated nearly 1.15 billion throughout the 
world. Mainly (two thirds) hypertensive patients were belonging 
from small and middle income nations [2]. During 2015, it has been 
estimated that hypertension is more prominent in male (1 in 4) in 
comparison to female (1 in 5) [3]. Globally including India, it has 
been projected that Hypertension is one of the main causes of death, 
studied in 2010 [4]. Worldwide targeted that decrease the 
occurrence of hypertension by 25% by 2025, out of all non-
communicable diseases [5]. 
The latest report regarding cardiovascular risk factors within Saudi 
community describes that the occurrence of hypertension is 31.4% 
which is remarkably raised in comparison to previous study [4, 6-8]. 
Due to the increased burden of Hypertension in the Community of 
Saudi Arabia, its duty of Healthcare provider keeps them aware and 
come forward for early detection and treatment. Pharmacotherapy 
of hypertension efficiently suppress hypertension related mortality 
and morbidity [9]. The chief goal of antihypertensive treatment is to 
prevent morbidity and mortality related to hypertension. Ultimate 
number of patients with hypertension suggested single, two or more 
antihypertensive medications [1]. Angiotensin Converting Enzyme 
Inhibitors (ACEIs), Angiotensin receptor blockers (ARBs), 
Beta Blockers (BBs), Calcium channel blockers (CCBs), centrally 
acting, Diuretics and Vasodilators have all been revealed to reduce 
problems of hypertension and may be used for early drug therapy 
[10, 11]. The Joint National Committee (JNC) during 2003 released 
series of guidelines endorses the proper antihypertensive therapy 
on the basis of best available evidence. The guidelines endorse 
Thiazide diuretics to be prescribed only or as part of combination 
treatment for most hypertensive patients deprived of compelling 
indications [11, 12]. Though, most latest published data indicated an 
increasing use of the more costly Angiotensin Converting Enzyme 
Inhibitors (ACEIs) and Calcium Channel Blockers (CCBs) in spite of 
the absence of evidence to support that they are superior to 
diuretics and beta blockers (BBs) in suppressing morbidity and 
mortality of heart diseases [13]. In spite of widespread broadcasting 
of the JNC guidelines, prescribing practices have long continued 
discrepant with recommendations [14]. Currently for the treatment 
of hypertension Saudi Arabia follows JNC 8 guideline [15]. 
Appropriate antihypertensive drug treatment is significant as the 
occurrence of hypertension has risen radically in the last three 
decades [16]. Somewhat deviance from evidence based guidelines in 
hypertension treatment contributes to the high cost of medicines 
and makes problems in providing affordable prescription drugs [17]. 
Improper prescribing is a noticed throughout the world challenging 
the health care delivery system [18]. Drug utilization studies (DUS) 
are potent investigative tools to determine the role of drugs in 
society [19].  
Among all the antihypertensive drugs Angiotensin Receptor Blocker 
(ARB) are most commonly drugs used specially in hypertension 
along associated disease. Hence, the current study was conducted 
with as Drug Utilization evaluation of Angiotensin Receptor Blocker 
(ARB) along with their adverse drug reactions ADRs in a tertiary 
care hospital. 
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MATERIALS AND METHODS 
Methodology 
Study design 
A Prospective, observational analysis of ADRs Patterns in patients 
with associated with ARBs used for treatment of Hypertension
the observed data were captured in special designed form
were utilized in calculation of different parameters
Study site 
Study were conducted in Cardiology outpatient department (OPD) of 
Teerthanker Mahaveer University (TMU) Hospital
Pradesh, 244001, India. 
Duration of study 
Study were conducted for a period of six months from 
2018 30th June 2018. 
Material used 
Naranjo’s Scale, Hartwig’s severity scale, WHO-UMC ADR assessments 
scale used for assessment of causality assessment ADRs.
Inclusion criteria 
• Patients who are diagnosed with hypertension and 
• Patients with co-morbid disease such as diabetes mellitus, renal 
disease (stage 1 and 2) and coronary artery disease associated with 
hypertension. 
Exclusion criteria 
• Pediatric patients 
 















Indication with or without co-morbidities 
A total 100 patients on antihypertensive therapy (ARBs) with or 
without co-morbidities, indicated with HTN (18%), HTN
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• Pregnant patients 
• Hypertensive patients not taking ARBs.
Sources of data 
All the relevant and necessary data will be collected from 
charts, Case sheets, Laboratory report and Patients hospital 
admission records. 
Data collection 
Prior to conduction of study and data collection, study protocol has 
been approved by the Institutional Ethics Committee (Ethical 
approval number: TMMC and
gender, drugs prescribed and 
special design form in Cardiology
interview after their informed
were archived kept as confidential.
Data analysis 
All the data were analysed in terms of frequency (n) and percentage 
(%). All the data were analysed by using 
RESULTS 
Demographic characteristics of 
Among all Hypertensive patients visited at study 
100 patients were included in the study during entire period of 
study as per inclusion and exclusion criteria of subject the study.
total 100 patients were on ARBs therapy where the maximum 
number of patients were 33 (33%) belongs to the age group 
y. Males 49 (49%) and Females 51 (51%). 
found in non-smokers (69%). Details are available in
and Azilsartan


























(28%), HTN-DM (17%), HT-hypothyroidism (5%), HTN
HTN-COPD (3%) and HTN-others 
Details are available in fig. 1. 
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Utilization of ARBs (Telmisartan, Olmesartan and Azilsartan) 
A total 100 patients were on antihypertensive therapy, ARBs were 
telmisartan (90%), Olmesartan (8%) and azilsartan (2%). In this 
study, the most common drug telmisartan drug was used. Details are 
available in fig. 2. 
Utilization of ARBs with or without other antihypertensive 
drugs in patients 
A total 252 prescriptions of ARBs (telmisartan, olmesartan and 
azilsartan) and ARBs with other class of antihypertensive drugs 
were used. The maximum number of 100 prescriptions (40%) in 
single therapy, 98 prescriptions (39%) in dual therapy, 51 
prescriptions (20%) in triple therapy and 3 prescriptions (1%) in 
tetra therapy. A total 100 patients were on antihypertensive therapy 
(ARBs) where the dual therapy (41%) was the most common 
therapy used than the single (38%), triple (18%) and tetra (3%) 
therapies. Details are available in table 2. 
Types of ADR produced by different ARBs among studied 
patients 
A total 32 ADR were reported in this study where the most numbers 
of probable ADRs were include Headache 24 (42.8%), Nausea 8 
(14.28%), Dizziness 7 (12.5%), Abdominal pain 5 (8.92%), Vomiting 
4 (7.14%), Cough 4 (7.14%), Muscle pain 2 (3.57%), Fever 1 (1.78%) 
and Diarrhea 1 (1.78%). Details are available in table 3. A total 32 
patients of ADRs of antihypertensive drugs (ARBs), the maximum 
numbers of ADRs were Telmisartan (88%), olmesartan (9%) and 
azilsartan (3%). Details are available in table 3. 
 
 
Fig. 2: Utilization of ARBs (Telmisartan, Olmesartan and Azilsartan) among studied patients 
 
Table 2: Utilization of ARBs with or without other antihypertensive drugs in patients among studied patients 










































Table 3: Types of ADR produced by different ARBs 
ADRs 
experienced 
Telmisartan Interventions Olmesartan Interventions Azilsartan Interventions 
Headache 22 Dechallenge  1 Symptomatic treatment 1 Symptomatic treatment 
Nausea 6 Symptomatic treatment 2 Symptomatic treatment Nil - 
Vomiting 4 Symptomatic treatment Nil - Nil - 
Fever 1 Dechallenge Nil - Nil - 
Diarrhea 1 Dechallenge Nil - Nil - 
Dizziness 6 Symptomatic treatment 1 Symptomatic treatment Nil - 
Cough 4 Dechallenge Nil - Nil - 
Abdominal 
pain 
5 Dechallenge Nil - Nil - 
Muscle pain 2 Symptomatic treatment Nil - Nil - 
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Age distribution in ADRs 
A total 32 patients of ADRs were on ARBs therapy where the 
maximum number of patients were 11 (34%) belongs to the age 
group of 41-50 y. A total 32 patients of ADRs of antihypertensive 
therapy, the maximum numbers of ADRs were found in females 
(56%) than males (44%). Details are available in table 4. 
Severity of ADR and ADR assessment 
WHO-UMC ADR assessments scale 
Causality assessment was done according to WHO-UMC assessment 
scale in this study where the terms were Probable 23 (72%), 
Possible 9 (28%) and others 0 (0%). Details are available in table 5. 
Naranjo’s scale  
The total 32 ADRs were reported in this study, causality assessment 
was done according to Naranjo’s scale where the terms are Probable 
21 (66%), Possible 11 (34%), Unlikely/Doubtful 0 (0%) and Definite 
0 (0%). Details are available in table 6. 
Hartwig’s severity scale  
To assess the severity of ADR, Hartwig’s scale (level 1 to 2 = Mild, 
level 3 to 4 = Moderate and level 5 to 7 = Severe) was widely used 
for this purpose in this study. A total 32 ADRs were found and the 
terms (on the basis of their levels) of severity were Mild 12 (38%) 
and Moderate 20 (62%). Details are available in table 7. 
 
Table 4: Age wise distribution of ADRs among studied patients 
Age in years No of patients % of patients 
31-40 4 12% 
41-50 11 34% 
51-60 6 19% 
61-70 7 22% 
71-80 4 13% 
Gender    
Male  14 44% 
Female 18 56% 
 
Table 5: Naranjo’s Scale WHO-UMC ADR assessments scale 




















Table 6: ADRs description according to naranjo’s scale 














Table 7: ADRs description according to Hartwig’s severity scale 
























The details of our study reported that females are more dominated 
over males which revels previous study [20]. This might be due to 
sedentary types of daily life which makes them more vulnerable to 
the adverse effects of dosages forms and accelerate the chances of 
ADRs. Older patients experienced more ADR which was greater than 
40 y with compare to younger ones that are fewer than 40 y which 
was also reported in other studies [21]. More ADRs are produced by 
Telmisartan 88% followed by Olmesartan and Azilsartan which also 
reveals to other studies conducted in Saudi Arabia [22]. Most 
common ADR is produced by Telmisartan i.e., Headache (22), 
Dizziness (6) and nausea (6), Olmesartan also shows Nausea (2) and 
headache (1) also but it was less in common comparison to 
Telmisartan. Azilsartan shows headache only in one patients 
however it also shows ADR in comparison to other ARBs. 
ADR shows different types of causality as per causality assessment 
tools. According to WHO-UMC assessment scale were probable 23 
(72%), Possible 9 (28%) and others 0 (0%). As per Naranjo’s scale 
Probable 21 (66%), Possible 11 (34%), Unlikely/Doubtful 0 (0%) 
and Definite 0 (0%). As per Hartwig’s severity scale (level 1 to 2 = 
Mild, level 3 to 4 = Moderate and level 5 to 7 = Severe) and severity 
were Mild 12 (38%) and Moderate 20 (62%).  
CONCLUSION 
Present study was designed and conducted in Indian hospital to 
monitor ADRs associated with ARBs used for treatment of 
Hypertension. The study finding showed that female was more prone 
to hypertension compared to male in the middle age group. Maximum 
ADRs observed with Telmisartan, followed by Olmesartan, and 
Azilsartan. Most of ADR were observed in this study were mild and 
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well tolerated by the patients. The main limitation of the mentioned 
study was the small sampled size and short duration study. So, I would 
suggest that more thorough study of special groups like paediatrics 
and pregnant women needs to be included in further study to identify 
strength of ADRs. And the outcome of therapy. 
LIMITATIONS 
In our study a small number of subjects were involved. Data from a 
larger number of subjects required to further assess the ADR 
appeared due to the use of ARB. 
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